Oncology Medical News about metastatic urothelial carcinoma;Vinflunine;platinum-pretreated

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma
Cancer, 06/25/09

Vaughn DJ et al. - In a study to evaluate the activity and safety of vinflunine in pts with locally advanced or metastatic urothelial carcinoma (UC) who developed disease progression within 12 mos of platinum-containing chemotherapy, it was shown that vinflunine demonstrates moderate activity in pts with platinum-pretreated UC. Toxicity is manageable and noncumulative.

Methods

Pts with UC were eligible if they received a prior platinum-based regimen in the neoadjuvant/adjuvant setting or as first-line treatment for advanced/metastatic disease and had developed disease progression within 12 mos.
Vinflunine was administered intravenously every 3 wks.
Pts with Karnofsky performance status of 80 or 90, impaired renal function, prior pelvic irradiation, or age 75 yrs received an initial dose of 280 mg/m2, which was escalated to 320 mg/m2 in cycle 2 if well tolerated.
All other pts received an initial dose of 320 mg/m2.
Primary endpoint was response rate.

Results

22 pts achieved a partial response, with a response rate of 15% with a median duration of response of 6.0 mos.
64 (42%) pts had stable disease.
Median progression-free survival was 2.8 mos, and median overall survival was 8.2 mos.
Myelosuppression was the most frequent adverse event, with grade 3 of 4 neutropenia reported in 58% of pts.
Grade 3 of 4 febrile neutropenia occurred in 10 (7%) pts.
Nonhematologic treatment-related events (grade 3 of 4) were generally manageable and included constipation (17%), asthenia/fatigue (13%), ileus (5%), and abdominal pain (5%).

<< Previous
Leucocyte depletion of perioperative blood transfusion does not...

Next >>
Revisiting the role of positron-emission tomography/computed...